A 3-member faculty panel will discuss treatment decisions for clinical case scenarios in advanced HR+ breast cancer. The panel will discuss challenging cases of patients and will offer guidance on evidence-based treatment choices for patients in the various lines of treatment and for managing treatment-related severe adverse events in these patients.

Learn more about the role of laboratory medicine professionals and pathologists, including a review of testing techniques and applications as well as lab-specific regulations and their impact on biomarker testing.

Hear finding and experiences of ACCC member programs who successfully orchestrated a quality improvement project to expand BRCA testing for eligible patients with breast cancer.

The Clinical Research Award recognizes individuals whose research has significantly and positively impacted the oncology patient, family, and/or community.

Optimal care delivery changes from place to place—what works best for one location and patient population may not be ideal for another. The same applies to cancer research. Understanding the needs of your patient population is critical to trial design and implementation. How can you proactively involve your community in cancer research activities? ​

With recent drug approvals and updates to clinical practice guidelines, many oncology practitioners find it challenging to stay abreast of changing treatment recommendations for patients with mCSPC (metastatic castration-sensitive prostate cancer). This activity aims to provide guidance on the latest in optimal management of mCSPC for oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The course will address challenges in optimal sequencing of care in mCSPC and will provide learners an opportunity to hear from experts regarding new research and clinical updates that can be translated into patient care strategies.

Community cancer centers are fast becoming sites for biomarker testing and precision medicine. As clinical research becomes a larger part of community cancer center operations, strengthening tissue collection procedures and considering the establishment of biospecimen repositories are critical concerns.

A panel of hematologic malignancy experts provide important and practical information for the assessment of measurable residual disease (MRD) as part of routine clinical practice for their patients with chronic lymphocytic leukemia.

Tune into sessions from the ACCC Big Data in IO Workshop, where expert faculty will delve into role of data in managing immune-related adverse events; applications of clinical trial and real-world data; the evolving integration of molecular data and patient-reported outcomes; and how new technologies will impact the future of data in immuno-oncology.

Review the current policies and regulations that drive costs related to biomarker testing.